Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity

Overview of attention for article published in Cancer Immunology, Immunotherapy, March 2012

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#5 of 2,959)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 51 news outlets

patent: 62 patents

Citations

dimensions_citation: 133 Dimensions

Readers on

mendeley: 172 Mendeley

Summary News Patents Dimensions citations

So far, Altmetric has seen 51 news stories from 51 outlets.

ASCO2016: Pfizer Presents Data From Phase Ib Trial Investigating Utomilumab (A 4-1BB Agonist) In Combination With A Checkpoint Inhibitor

Biospace, 06 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK--…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination ...

Wall Street Online Germany, 04 Jun 2016

Pfizer Inc. (NYSE:PFE) today announced results from a Phase 1b trial of Pfizer’s investigational immunotherapy agent utomilumab …

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

TMCnet.com, 04 Jun 2016

] Pfizer Inc. (NYSE:PFE) today announced results from a Phase 1b trial of Pfizer's investigational immunotherapy agent…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in...

Stockhouse, 04 Jun 2016

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

News Channel, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

ABC 7 News KSWO, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

KTRE, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

WALB, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

KTEN, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

CW: Richmond, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

Fox 8 WVUE, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

Fox 14 News, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

WTVM, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

2 News, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

KX News, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

KAIT-TV, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

News Channel 6, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

KUSI News, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

KiiiTV 3 , 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

KHQ, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

Erie News Now, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

WSFA , 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

WLOX, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

NewsOn6, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

Kuam, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

WLTZ, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

KSLA News 12, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

WFLX Fox 29, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

Hawaii News Now, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

WBOC 16, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

KLKN-TV Eyewitness News, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

News Channel 10, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

KCENG12, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

KPLC 7 News, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

WMBF News, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

Mississippi News Now , 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK --(BUSIN…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

BioMed Reports, 04 Jun 2016

NEW YORK--( BUSINESS WIRE )-- Pfizer Inc. (NYSE:PFE) today announced results from a Phase 1b trial of Pfizer’s investigational…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

Noodls, 04 Jun 2016

Pfizer Inc. (via noodls) / NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced results from a Phase 1b trial of…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor - Press Release

Digital Journal, 04 Jun 2016

NEW YORK--(Business Wire)--Pfizer Inc. (NYSE:PFE) today announced results from a Phase 1b trial of Pfizer’s investigational…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

Benzinga, 04 Jun 2016

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE ) today announced results from a Phase 1b trial of Pfizer's investigational…

News story from Bloomberg on Saturday 04 June 2016

Bloomberg, 04 Jun 2016

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

Business Wire, 04 Jun 2016

NEW YORK--( BUSINESS WIRE )--Pfizer Inc. (NYSE:PFE) today announced results from a Phase 1b trial of Pfizer’s investigational…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

Stock Nod: Quotes, 04 Jun 2016

. (NYSE:PFE) today announced results from a Phase 1b trial of Pfizer’s investigational immunotherapy agent utomilumab (the…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

Yahoo! Finance USA, 04 Jun 2016

NEW YORK--(BUSINESS WIRE)-- (PFE) today announced results from a Phase 1b trial of Pfizer’s investigational immunotherapy agent…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

NASDAQ, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK--(BUSINE…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

Yahoo! Finance UK , 04 Jun 2016

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. ( PFE ) today announced results from a Phase 1b trial of Pfizer’s investigational…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

CNBC, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK--(BUSINE…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

Yahoo! Finance Singapore, 04 Jun 2016

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. ( PFE ) today announced results from a Phase 1b trial of Pfizer’s investigational…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

Minyanville: Finance , 04 Jun 2016

Pfizer Inc. (NYSE:PFE) today announced results from a Phase 1b trial of Pfizer’s investigational immunotherapy agent utomilumab …

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

Equities.com, 04 Jun 2016

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations NEW YORK--(BUSINE…

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

Drugs.com, 04 Jun 2016

- Pfizer Inc. (NYSE:PFE) today announced results from a Phase 1b trial of Pfizer’s investigational immunotherapy agent…